-

Cycle Pharmaceuticals Features in the Sunday Times Tech Track Ones to Watch 2020

original

CAMBRIDGE, England--(BUSINESS WIRE)--Cycle Pharmaceuticals, a privately-owned, global, patient-dedicated biotechnology company focused on developing and delivering medicines for rare diseases, has been featured as one of the Sunday Times 10 Tech Track Ones to Watch 2020.

The Sunday Times launched the Tech Track 100 list 20 years ago to recognise Britain’s fastest-growing private technology companies. The Tech Track 10 Ones to Watch showcases companies that do not yet meet the criteria of the main Tech Track 100 league table, but which have achieved strong sales growth, are forecasting strong sales growth, and have innovative technologies.

The Sunday Times Tech Track 100 supplement including the 10 Ones to Watch was published on Sunday 6th September 2020, within the business section of the Sunday Times. The digital edition can be downloaded from: www.fasttrack.co.uk.

Earlier this week, Cycle announced a $25m debt financing from Deutsche Bank AG.

About Cycle Pharmaceuticals

Cycle Pharmaceuticals was founded in 2012 with the sole aim of delivering best-in-class drug treatments and services to the under-served rare disease patient community. We focus on rare metabolic and neurological genetic conditions. Cycle is headquartered in Cambridge, UK and has offices in Boston, Mass. (USA). For more information, please visit www.cyclepharma.com and follow us on Twitter, LinkedIn, Facebook and Instagram.

Contacts

Cycle Pharmaceuticals
Paula Bekinschtein
Head of Global Marketing
Email: marketing@cyclepharma.com
Tel.: +44-1223-354118

Industry:

Cycle Pharmaceuticals

Release Summary
Cycle Pharmaceuticals Features in the Sunday Times Tech Track Ones to Watch 2020
Release Versions
EnglishSpanish (Summary)GermanFrenchItalianDutch (Summary)
Hashtags
#CyclePharma
#OTW
#SageTechTrack100
#orphandrugs
#rarediseases

Contacts

Cycle Pharmaceuticals
Paula Bekinschtein
Head of Global Marketing
Email: marketing@cyclepharma.com
Tel.: +44-1223-354118

Social Media Profiles
Cycle Pharmaceuticals on Facebook
Cycle Pharmaceuticals on Instagram
Cycle Pharmaceuticals on LinkedIn
Cycle Pharmaceuticals on Twitter
More News From Cycle Pharmaceuticals

Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics

CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle”) is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: APLT; “Applied”), a clinical-stage biopharmaceutical company. Applied’s lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Deh...

Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer

CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle” or “Parent”) today announces that AT2B, Inc., a Delaware corporation (“Purchaser”) and indirect wholly owned subsidiary of Cycle, has extended the expiration date of its tender offer to purchase all of the outstanding shares of common stock, par value $0.0001 per share of Applied Therapeutics, Inc., a Delaware corporation (“Applied”) for (i) $0.088 per share, net to the seller in cash, without interest, plus (i...

Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer

CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle” or “Parent”) today announces that AT2B, Inc., a Delaware corporation (“Purchaser”) and indirect wholly owned subsidiary of Cycle, has extended the expiration date of its tender offer to purchase all of the outstanding shares of common stock, par value $0.0001 per share of Applied Therapeutics, Inc., a Delaware corporation (“Applied”) for (i) $0.088 per share, net to the seller in cash, without interest, plus (i...
Back to Newsroom